Selpercatinib (Sepadx) 40mg — RET-Driven Cancer | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Info

Selpercatinib is an oral, highly selective RET kinase inhibitor. This product is marketed as Sepadx and manufactured by Bigbear Pharmaceutical (Lao) Co., Ltd.. Selpercatinib was first approved by the U.S. FDA in 2020 as the first therapy specifically targeting RET-driven cancers. Sepadx is a generic version of selpercatinib offered at a more accessible price.

What Is Selpercatinib Used For?

Selpercatinib is used to treat cancers driven by RET gene alterations — specifically RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), RET fusion-positive thyroid cancer, and other RET fusion-positive solid tumors. It is given only after a test confirms the presence of a RET fusion or mutation.

How Does Selpercatinib Work?

RET is a receptor tyrosine kinase that, when altered by a gene fusion or mutation, drives uncontrolled cancer cell growth. Selpercatinib is a highly selective RET kinase inhibitor: it binds and blocks RET, shutting down the downstream signaling that fuels tumor growth. Because it crosses the blood-brain barrier, it is effective against brain metastases — a key advantage for patients with central nervous system involvement.

Indications

  • RET fusion-positive locally advanced or metastatic NSCLC
  • RET-mutant advanced or metastatic medullary thyroid cancer (MTC)
  • RET fusion-positive advanced or metastatic thyroid cancer (radioactive iodine-refractory, when applicable)
  • RET fusion-positive locally advanced or metastatic solid tumors

Dosage

The recommended dose of selpercatinib in adults and adolescents 12 years and older is based on body weight: 120 mg orally twice daily for patients under 50 kg, and 160 mg orally twice daily for patients 50 kg or greater, until disease progression or unacceptable toxicity. Capsules/tablets are available in 40 mg, 80 mg, 120 mg, and 160 mg strengths. Dose reductions are required for severe hepatic impairment.

Side Effects

The most common side effects of selpercatinib include:

  • Dry mouth
  • Diarrhea
  • Hypertension (high blood pressure)
  • Fatigue
  • Edema (swelling)
  • Constipation
  • Rash
  • Elevated liver enzymes (ALT/AST)

Serious side effects include hepatotoxicity, interstitial lung disease (ILD)/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, and hypersensitivity reactions. Liver function and blood pressure should be monitored regularly during treatment.

Storage

Store selpercatinib at room temperature (20°C to 25°C / 68°F to 77°F). Keep in the original container, tightly closed, and out of reach of children. Do not use after the expiration date printed on the package.

Why Choose the GLT?

GIVE LIFE TIME LIMITED (GLT) sources genuine, manufacturer-sealed Sepadx (selpercatinib) and ships internationally with reliable logistics. We support both institutional buyers (hospitals, pharmacies, distributors) and individual patients, with responsive customer service and clear ordering guidance throughout the process.

How to Order

Contact our team via WhatsApp or email to confirm current availability, pricing, and shipping options for your region. Provide the required strength and quantity, and we will guide you through the ordering and delivery process.

FAQ

Q: Is Sepadx a chemotherapy?
No. Selpercatinib is a targeted therapy (a RET kinase inhibitor), not a conventional chemotherapy.

Q: Who can take Sepadx?
It is for patients whose cancer has a confirmed RET gene fusion or RET mutation, as detected by a molecular test.

Q: How is Sepadx taken?
It is taken orally, twice daily, with the dose based on body weight (120 mg or 160 mg twice daily for adults).

Related Oncology Products

Selpercatinib (Retevmo) — RET-Driven Lung & Thyroid Cancer | GLT

FDA-approved selective RET kinase inhibitor for RET fusion-positive NSCLC and thyroid cancer

Zongertinib (LuciZonger) 60mg | Laos Generic HER2 Inhibitor for NSCLC | GLT

Registered Laos generic zongertinib for HER2-mutant NSCLC, 60mg × 60 tablets.

Selpercatinib (Selcaxen) 40mg — RET-Driven Cancer | GLT

Affordable generic selpercatinib (Everest) for RET-driven lung and thyroid cancer

Zongertinib (Hernexeos) 60mg | China-Sourced HER2 Inhibitor for NSCLC | GLT

NMPA-approved originator zongertinib for HER2-mutant NSCLC, 60mg × 60 tablets.

Sotoldx (Sotorasib) 120mg*56's | Generic KRAS G12C Inhibitor | BigBear Pharmaceutical Co., Ltd. | GLT

Generic sotorasib (KRAS G12C inhibitor) by BigBear Pharmaceutical Co., Ltd. (Laos) — an affordable alternative...

Sotakras (Sotorasib) 120mg*56's | Generic KRAS G12C Inhibitor | Ziska Pharmaceuticals Ltd. | GLT

Generic sotorasib (KRAS G12C inhibitor) by Ziska Pharmaceuticals Ltd. (Bangladesh) — an affordable alternative to...

Lumakras (Sotorasib) 120mg Tablets | KRAS G12C NSCLC & mCRC | Amgen US | GLT

Amgen's first-in-class KRAS G12C inhibitor, FDA-approved for KRAS G12C-mutated NSCLC and mCRC.

Oysiendx (Osimertinib) 80mg*30 | Laos Generic EGFR TKI | GLT

Bigbear Pharmaceutical (Lao) — affordable osimertinib 80mg generic for EGFR-mutant NSCLC